An Open-Label, Multicenter, Phase I Trial Evaluating the Safety and Pharmacokinetics of Escalating Doses of BTCT4465A in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

What is the purpose of this trial?

This study is designed to evaluate the safety and pharmacokinetics of BTCT4465A when administered as a single agent by intravenous (IV) infusion to participants with relapsed or refractory B-cell NHL and CLL. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.



Genentech, Inc.

Start Date: 05/03/2016

End Date: 10/31/2020

Last Updated: 10/09/2018

Study HIC#: 1509016491

Get Involved

For more information about this study, contact:
Laura Leary
laura.leary@yale.edu

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image